Lung Cancer Dispatch
Follow
Find tag "Tafinlar"
3.4K views | +1 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

Cancer Drug Tafinlar Receives Breakthrough Therapy Designation for Lung Cancer

Cancer Drug Tafinlar Receives Breakthrough Therapy Designation for Lung Cancer | Lung Cancer Dispatch | Scoop.it

The application for dabrafenib (Tafinlar) as a treatment for certain lung cancer cases has been given a boost with the U.S. Food and Drug Administration (FDA) designating it a breakthrough therapy. Tafinlar is being investigated as a therapy for patients with non-small cell lung cancer (NSCLC) who have a mutation called BRAF V600E in the BRAF gene and have received at least one previous round of chemotherapy. In a recent clinical trial, Tafinlar exhibited antitumor activity in such patients. The breakthrough therapy designation provides increased drug development guidance from the FDA and accelerated approval for drugs that treat serious or life-threatening conditions and that provide a substantial improvement over currently available treatments. Tafinlar is already approved for use in certain types of skin cancer.

Cancer Commons's insight:

ASCO Post  |  Jan 13, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Cancer Drug Targeting BRAF Gene May Be Effective in Lung Cancer

A small subset of patients with non-small cell lung cancer (NSCLC), especially those with lung adenocarcinoma, have a mutation in the BRAF gene called V600E. An ongoing phase II clinical trial is investigating whether the BRAF inhibitor dabrafenib (Tafinlar) benefits patients with this mutation. Tafinlar is currently approved for treatment of the skin cancer melanoma. Recently released trial results show that the drug partially shrank tumors in 40% of advanced NSCLC patients whose cancer had worsened after at least one round of chemotherapy. Another 20% of study participants maintained stable disease (tumors neither shrinking nor growing). Almost half of the patients currently remain on the treatment. These findings are the first evidence that treatments targeting the BRAF V600E mutation may be effective in lung cancer.

Cancer Commons's insight:

ASCO Daily News | June 4, 2013

more...
No comment yet.